一圖看懂百奧賽圖-B(02315.HK)IPO
百奧賽圖-B(02315.HK)於8月19日-8月24日招股,擬全球發售2175.85萬股H股,其中香港公開發售佔10%,國際發售佔90%,另有15%超額配股權。每股發售價25.22港元,每手500股,入場費12737港元,此次上市高盛、中金公司爲聯席保薦人,預期9月1日正式掛牌上市。
百奧賽圖是一家成立於2009年的生物製藥及臨牀前研究服務創收公司,目前已建立12項候選藥物組成的精選抗體藥物產品管線,其中2個產品在國際多中心(MRCT)臨牀試驗II期,2個在臨牀試驗I期。
此次上市所籌資金用途:約70%擬用於爲公司核心產品的進一步臨牀研發提供資金;約15%擬用於根據公司的千鼠萬抗計劃爲抗體藥物發現及開發提供資金;約10%擬用於公司其他管線產品的臨牀前及臨牀開發;約5%將用作營運資金及其他一般公司用途。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.